cyramza
cyramza Uses, Dosage, Side Effects, Food Interaction and all others data.
cyramza is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. cyramza is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
| Trade Name | cyramza |
| Availability | Prescription only |
| Generic | Ramucirumab |
| Ramucirumab Other Names | Ramucirumab |
| Related Drugs | Opdivo, methotrexate, Keytruda, capecitabine, pembrolizumab, fluorouracil, doxorubicin, cisplatin, Tagrisso, Avastin |
| Weight | 10mg/ml, |
| Type | Injection, Solution, Infusion, Intravenous Solution |
| Formula | C6374H9864N1692O1996S46 |
| Weight | 143600.0 Da |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Eli Lilly, Eli Lilly And Company Limited |
| Available Country | Saudi Arabia, Australia, United Kingdom, United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
cyramza is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
cyramza is also used to associated treatment for these conditions: Advanced Gastric Cancer, Advanced gastro-esophageal junction adenocarcinoma, Refractory, metastatic Colorectal cancer, Refractory, metastatic Non small cell lung cancer
How cyramza works
cyramza is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.
Toxicity
cyramza packaging includes warnings for arterial thromboembolic events, hypertension, infusion-related reactions, gastrointestinal perforation, clinical deterioration in patients with cirrhosis, and reversible posterior leukoencephalopathy syndrome. The most common reactions observed in single-agent-treated patients at a rate of >10% and >2% higher than placebo were hypertension and diarrhea. The most common adverse reactions observed in patients treated with ramucirumab plus paclitaxel at a rate of of >30% and >2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis.
Food Interaction
No interactions found.cyramza Drug Interaction
Major: aspirin, heparinUnknown: paclitaxel protein-bound, charcoal, doxorubicin, darbepoetin alfa, fluticasone, diphenhydramine, calcium / vitamin d, doxazosin, sulfamethoxazole / trimethoprim, ubiquinone, prochlorperazine, copper gluconate, ubiquinone, vitamin a topical, bioflavonoids, sotalol, cyanocobalamin, cholecalciferol
cyramza Disease Interaction
Major: bleeding, GI perforationModerate: hypothyroidism, liver dysfunction, hypertension, PRES, proteinuria, thromboembolic disorders
Volume of Distribution
5.5 L
Half Life
15 days
Clearance
0.014 L/hour
Innovators Monograph
You find simplified version here cyramza
